2021
Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support
Crothers K, DeFaccio R, Tate J, Alba PR, Goetz MB, Jones B, King JT, Marconi V, Ohl ME, Rentsch CT, Rodriguez-Barradas MC, Shahrir S, Justice AC, Akgün KM, Group F. Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support. European Respiratory Journal 2021, 60: 2102532. PMID: 34824060, PMCID: PMC8841623, DOI: 10.1183/13993003.02532-2021.Peer-Reviewed Original ResearchConceptsIntensive respiratory supportHospitalised COVID-19 patientsCOVID-19 patientsNasal cannulaEarly dexamethasoneRespiratory supportSevere acute respiratory syndrome coronavirus 2Low-flow nasal cannulaAcute respiratory syndrome coronavirus 2Coronavirus disease 2019 (COVID-19) patientsRespiratory syndrome coronavirus 2Cox proportional hazards modelUS Veterans Affairs hospitalsSyndrome coronavirus 2Veterans Affairs hospitalProportional hazards modelCOVID-19Prior corticosteroidsCause mortalityMortality benefitTotal patientsCoronavirus 2Unexposed groupReal-world findingsEarly initiationCOVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients
Stewart M, Rodriguez-Watson C, Albayrak A, Asubonteng J, Belli A, Brown T, Cho K, Das R, Eldridge E, Gatto N, Gelman A, Gerlovin H, Goldberg SL, Hansen E, Hirsch J, Ho YL, Ip A, Izano M, Jones J, Justice AC, Klesh R, Kuranz S, Lam C, Mao Q, Mataraso S, Mera R, Posner DC, Rassen JA, Siefkas A, Schrag A, Tourassi G, Weckstein A, Wolf F, Bhat A, Winckler S, Sigal EV, Allen J. COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. PLOS ONE 2021, 16: e0248128. PMID: 33730088, PMCID: PMC7968637, DOI: 10.1371/journal.pone.0248128.Peer-Reviewed Original ResearchConceptsHospitalized COVID-19 patientsCOVID-19 patientsUse of hydroxychloroquineElectronic health recordsAdverse eventsTreatment groupsCOVID-19Administration of hydroxychloroquineReagan-Udall FoundationProportional hazards modelHealth systems researchHospitalized patientsElevated riskPropensity score methodsHazards modelHydroxychloroquinePatientsSignificant global threatPharmaceutical interventionsAzithromycinHealth recordsMortalityCOVID-19 pandemicCancer researchTreatment
2020
Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index
King JT, Yoon JS, Rentsch CT, Tate JP, Park LS, Kidwai-Khan F, Skanderson M, Hauser RG, Jacobson DA, Erdos J, Cho K, Ramoni R, Gagnon DR, Justice AC. Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index. PLOS ONE 2020, 15: e0241825. PMID: 33175863, PMCID: PMC7657526, DOI: 10.1371/journal.pone.0241825.Peer-Reviewed Original ResearchConceptsCharlson Comorbidity IndexVeterans Health AdministrationVACO IndexValidation cohortMedical administrative dataDevelopment cohortSARS-CoV-2 testing resultsMortality indexICD-10 diagnosis codesUS Veterans Health AdministrationSARS-CoV-2 infectionPre-existing medical conditionsCOVID-19 mortality riskPeripheral vascular diseaseCOVID-19 patientsCOVID-19 infectionCOVID-19 mortalitySARS-CoV-2Administrative dataLogistic regression modelsRace/ethnicityCohort subgroupsComorbidity indexOverall mortalityComorbid conditionsA mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm
Garvin M, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, Mast AE, Justice A, Aronow B, Jacobson D. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. ELife 2020, 9: e59177. PMID: 32633718, PMCID: PMC7410499, DOI: 10.7554/elife.59177.Peer-Reviewed Original ResearchConceptsBronchoalveolar lavage fluidCOVID-19COVID-19 patientsBradykinin stormRAS receptorsLavage fluidVasopressor systemsBradykinin levelsVascular dilationVascular permeabilityBradykinin receptorsTherapeutic interventionsTherapeutic intervention pointNovel molecular mechanismDecreased expressionACE2Atypical patternsDisease mechanismsHypotensionAngiotensinMultiple tissuesCritical imbalanceReceptorsMolecular mechanismsVirus